Tibsovo Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

tibsovo

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastilised ained - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Tomahawk® 200 EC Estonia - Tiếng Estonia - Adama

tomahawk® 200 ec

adama - emulsioonikontsentraat - fluroksüpüür - herbitsiidid

Agil® 100 EC Estonia - Tiếng Estonia - Adama

agil® 100 ec

adama - emulsioonikontsentraat - propakvisafop - herbitsiidid

Cleave® Estonia - Tiếng Estonia - Adama

cleave®

adama - suspo-emulsioon - florasulaam + fluroksüpüür - herbitsiidid

Leopard® Estonia - Tiếng Estonia - Adama

leopard®

adama - emulsioonikontsentraat - kvisalofop-p-etüül - herbitsiidid

Mixin® Estonia - Tiếng Estonia - Adama

mixin®

adama - suspo-emulsioon - florasulaam + fluroksüpüür - herbitsiidid

Poleposition® ja Mirador® segu Estonia - Tiếng Estonia - Adama

poleposition® ja mirador® segu

adama - emulsioonikontsentraat / suspensioonikontsentraat - asoksüstrobiin + protiokonasool - fungitsiidid

Legacy® 500 SC Estonia - Tiếng Estonia - Adama

legacy® 500 sc

adama - suspensioonikontsentraat - diflufenikaan - herbitsiidid

Mirador® 250 SC Estonia - Tiếng Estonia - Adama

mirador® 250 sc

adama - suspensioonikontsentraat - asoksüstrobiin - fungitsiidid

Opdualag Liên Minh Châu Âu - Tiếng Estonia - EMA (European Medicines Agency)

opdualag

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.